摘要
The suppressors of cytokine signaling (SOCS) family is thought to act largely as a negative regulator of signaling by cytokines and some growth factors. Surprisingly, the SOCS-6 transgenics had no significant defects in the cytokine signaling and hematopoietic system but displayed significant improvements in glucose metabolism. Insulin stimulation of Akt/protein kinase B was also potentiated. Biochemical analysis showed that, after insulin stimulation, SOCS-6 interacted with the monomeric p85 subunit of class-Ia phosphoinositide (PI) 3-kinase but not with p85/p110 dimers. Furthermore, SOCS-6 expression is transiently increased by serum and insulin in normal fibroblasts. However, both the mRNA and protein of SOCS-6 were rapidly degraded after induction by insulin. The degradation of the SOCS-6 protein was partially inhibited by a proteasome inhibitor, suggesting a proteasome-mediated degradation mechanism. In contrast, SOCS-6-associated p85 was not degraded and could be recruited to the newly synthesized SOCS-6 molecules in the presence of insulin, suggesting that SOCS-6 expression and its interaction with p85, but not the degradation, is regulated by insulin. The phenotype of SOCS-6 transgenic mice bears a striking resemblance to p85 knock-out mouse models in which glucose metabolism stimulated by insulin is significantly improved despite reduced activation of PI 3-kinase. This suggests that monomeric p85 might play a physiologically important role in attenuating signaling through PI 3-kinase-dependent pathways in unstimulated cells. Therefore, our results indicate that SOCS-6 may provide a dynamically regulated mechanism by which insulin can transiently overcome the negative effects that p85 monomers have on signaling via PI 3-kinase-dependent signaling pathways. The suppressors of cytokine signaling (SOCS) family is thought to act largely as a negative regulator of signaling by cytokines and some growth factors. Surprisingly, the SOCS-6 transgenics had no significant defects in the cytokine signaling and hematopoietic system but displayed significant improvements in glucose metabolism. Insulin stimulation of Akt/protein kinase B was also potentiated. Biochemical analysis showed that, after insulin stimulation, SOCS-6 interacted with the monomeric p85 subunit of class-Ia phosphoinositide (PI) 3-kinase but not with p85/p110 dimers. Furthermore, SOCS-6 expression is transiently increased by serum and insulin in normal fibroblasts. However, both the mRNA and protein of SOCS-6 were rapidly degraded after induction by insulin. The degradation of the SOCS-6 protein was partially inhibited by a proteasome inhibitor, suggesting a proteasome-mediated degradation mechanism. In contrast, SOCS-6-associated p85 was not degraded and could be recruited to the newly synthesized SOCS-6 molecules in the presence of insulin, suggesting that SOCS-6 expression and its interaction with p85, but not the degradation, is regulated by insulin. The phenotype of SOCS-6 transgenic mice bears a striking resemblance to p85 knock-out mouse models in which glucose metabolism stimulated by insulin is significantly improved despite reduced activation of PI 3-kinase. This suggests that monomeric p85 might play a physiologically important role in attenuating signaling through PI 3-kinase-dependent pathways in unstimulated cells. Therefore, our results indicate that SOCS-6 may provide a dynamically regulated mechanism by which insulin can transiently overcome the negative effects that p85 monomers have on signaling via PI 3-kinase-dependent signaling pathways. The suppressors of cytokine signaling family (SOCS) 1The abbreviations used are: SOCS, suppressors of cytokine signaling; SH2, Src homology 2; CHO, Chinese hamster ovary; CIS, cytokine-inducible SH2 protein; ERK, extracellular signal-regulated kinase; IR, insulin receptor; IRS, IR substrate; JAK, Janus kinase; MEF, mouse embryonic fibroblast; PI, phosphoinositide; PIP3, phosphatidylinositol 1,4,5-trisphosphate; PKB, protein kinase B; STAT, signal transducers and activators of transcription. 1The abbreviations used are: SOCS, suppressors of cytokine signaling; SH2, Src homology 2; CHO, Chinese hamster ovary; CIS, cytokine-inducible SH2 protein; ERK, extracellular signal-regulated kinase; IR, insulin receptor; IRS, IR substrate; JAK, Janus kinase; MEF, mouse embryonic fibroblast; PI, phosphoinositide; PIP3, phosphatidylinositol 1,4,5-trisphosphate; PKB, protein kinase B; STAT, signal transducers and activators of transcription. consists of eight proteins (CIS and SOCS-1–7) that were first characterized as negative feedback regulators for cytokine receptor signaling. Members of the SOCS family share a common structure containing a central SH2 domain and a C-terminal SOCS box, and variability in their sequences at the N terminus probably confers specificity of function (1Kile B.T. Schulman B.A. Alexander W.S. Nicola N.A. Martin H.M. Hilton D.J. Trends Biochem. Sci. 2002; 27: 235-241Abstract Full Text Full Text PDF PubMed Scopus (357) Google Scholar). The SH2 domain allows the SOCS proteins to interact with tyrosine-phosphorylated target proteins such as Janus kinases (JAKs), and the SOCS box is suggested to act as a common binding domain for a large family of E3 ubiquitin protein ligases (2Zhang J.G. Metcalf D. Rakar S. Asimakis M. Greenhalgh C.J. Willson T.A. Starr R. Nicholson S.E. Carter W. Alexander W.S. Hilton D.J. Nicola N.A. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 13261-13265Crossref PubMed Scopus (137) Google Scholar, 3Kamura T. Burian D. Yan Q. Schmidt S.L. Lane W.S. Querido E. Branton P.E. Shilatifard A. Conaway R.C. Conaway J.W. J. Biol. Chem. 2001; 276: 29748-29753Abstract Full Text Full Text PDF PubMed Scopus (127) Google Scholar, 4Kamura T. Sato S. Haque D. Liu L. Kaelin Jr., W.G. Conaway R.C. Conaway J.W. Genes Dev. 1998; 12: 3872-3881Crossref PubMed Scopus (498) Google Scholar). In this manner, molecules containing the SOCS domain may regulate protein degradation by targeting proteins for ubiquitination and, subsequently, for proteasome-mediated degradation (5Kamizono S. Hanada T. Yasukawa H. Minoguchi S. Kato R. Minoguchi M. Hattori K. Hatakeyama S. Yada M. Morita S. Kitamura T. Kato H. Nakayama K. Yoshimura A. J. Biol. Chem. 2001; 276: 12530-12538Abstract Full Text Full Text PDF PubMed Scopus (268) Google Scholar). CIS, SOCS-1, SOCS-2, and SOCS-3 are the most widely studied members of SOCS family, and it is known that the expression of these genes is rapidly induced by an array of stimuli such as cytokines (6Hortner M. Nielsch U. Mayr L.M. Johnston J.A. Heinrich P.C. Haan S. J. Immunol. 2002; 169: 1219-1227Crossref PubMed Scopus (109) Google Scholar, 7Lebel E. Vallieres L. Rivest S. Endocrinology. 2000; 141: 3749-3763Crossref PubMed Google Scholar, 8Berlato C. Cassatella M.A. Kinjyo I. Gatto L. Yoshimura A. Bazzoni F. J. Immunol. 2002; 168: 6404-6411Crossref PubMed Scopus (226) Google Scholar) and growth factors (9Greenhalgh C.J. Metcalf D. Thaus A.L. Corbin J.E. Uren R. Morgan P.O. Fabri L.J. Zhang J.G. Martin H.M. Willson T.A. Billestrup N. Nicola N.A. Baca M. Alexander W.S. Hilton D.J. J. Biol. Chem. 2002; 277: 40181-40184Abstract Full Text Full Text PDF PubMed Scopus (143) Google Scholar, 10Denson L.A. Held M.A. Menon R.K. Frank S.J. Parlow A.F. Arnold D.L. Am. J. Physiol. 2003; 284: G646-G654Crossref PubMed Scopus (84) Google Scholar, 11Dogusan Z. Hooghe-Peters E.L. Berus D. Velkeniers B. Hooghe R. J. Neuroimmunol. 2000; 109: 34-39Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar), including insulin (12Rui L. Yuan M. Frantz D. Shoelson S. White M.F. J. Biol. Chem. 2002; 277: 42394-42398Abstract Full Text Full Text PDF PubMed Scopus (699) Google Scholar, 13Sadowski C.L. Choi T.S. Le M. Wheeler T.T. Wang L.H. Sadowski H.B. J. Biol. Chem. 2001; 276: 20703-20710Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar). The increased levels of CIS, SOCS-1, SOCS-2, and SOCS-3 result in feedback inhibition of a wide variety of agonist-induced signaling pathways (14Krebs D.L. Hilton D.J. J. Cell Sci. 2000; 113: 2813-2819Crossref PubMed Google Scholar). However, this finding is not just restricted to cytokine signaling. For example, in the case of insulin signaling there is evidence that the overexpression of SOCS-1 and SOCS-3 attenuates insulin signaling by binding to the insulin receptor (IR) directly and targeting the insulin receptor substrate molecules (IRS-1 and IRS-2) for proteasome-mediated degradation (12Rui L. Yuan M. Frantz D. Shoelson S. White M.F. J. Biol. Chem. 2002; 277: 42394-42398Abstract Full Text Full Text PDF PubMed Scopus (699) Google Scholar, 15Emanuelli B. Peraldi P. Filloux C. Chavey C. Freidinger K. Hilton D.J. Hotamisligil G.S. Van Obberghen E. J. Biol. Chem. 2001; 276: 47944-47949Abstract Full Text Full Text PDF PubMed Scopus (369) Google Scholar, 16Mooney R.A. Senn J. Cameron S. Inamdar N. Boivin L.M. Shang Y. Furlanetto R.W. J. Biol. Chem. 2001; 276: 25889-25893Abstract Full Text Full Text PDF PubMed Scopus (208) Google Scholar). Thus, SOCS molecules appear to act as part of a classical negative feedback loop, inhibiting the signaling pathways that initially led to the expression of SOCS genes. However, an important feature of this system is that it allows for regulatory cross-talk between signaling pathways. For example, the increase in SOCS-1 and SOCS-3 expression by cytokines has been suggested as the mechanism by which they bring about the attenuation in insulin signaling that causes insulin resistance associated with the development of type 2 diabetes (15Emanuelli B. Peraldi P. Filloux C. Chavey C. Freidinger K. Hilton D.J. Hotamisligil G.S. Van Obberghen E. J. Biol. Chem. 2001; 276: 47944-47949Abstract Full Text Full Text PDF PubMed Scopus (369) Google Scholar). Despite structural similarities in SOCS proteins, evidence is now emerging to show that different members of the SOCS family have distinct roles. For example, the regulation and function of SOCS-1 and SOCS-3 in cytokine signaling appears to be very similar to both binding to JAKs and the inhibition of kinase activity. However, mice lacking SOCS-1 or SOCS-3 showed completely different phenotypes (17Marine J.C. Topham D.J. McKay C. Wang D. Parganas E. Stravopodis D. Yoshimura A. Ihle J.N. Cell. 1999; 98: 609-616Abstract Full Text Full Text PDF PubMed Scopus (443) Google Scholar, 18Alexander W.S. Starr R. Fenner J.E. Scott C.L. Handman E. Sprigg N.S. Corbin J.E. Cornish A.L. Darwiche R. Owczarek C.M. Kay T.W. Nicola N.A. Hertzog P.J. Metcalf D. Hilton D.J. Cell. 1999; 98: 597-608Abstract Full Text Full Text PDF PubMed Scopus (643) Google Scholar, 19Starr R. Metcalf D. Elefanty A.G. Brysha M. Willson T.A. Nicola N.A. Hilton D.J. Alexander W.S. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 14395-14399Crossref PubMed Scopus (376) Google Scholar, 20Marine J.C. McKay C. Wang D. Topham D.J. Parganas E. Nakajima H. Pendeville H. Yasukawa H. Sasaki A. Yoshimura A. Ihle J.N. Cell. 1999; 98: 617-627Abstract Full Text Full Text PDF PubMed Scopus (309) Google Scholar), suggesting that the roles of SOCS-1 and SOCS-3 in signaling outside the cytokine pathways might differ. Furthermore, we observed previously that CIS negatively regulates IL-2 signaling but promotes T-cell receptor stimulation of NF-κB and mitogen-activated protein kinase pathways in T-cells (21Li S. Chen S. Xu X. Sundstedt A. Paulsson K.M. Anderson P. Karlsson S. Sjogren H.O. Wang P. J. Exp. Med. 2000; 191: 985-994Crossref PubMed Scopus (83) Google Scholar). This is suggestive of a dual function of CIS in the negative regulation of cytokine signaling and the positive regulation of T-cell receptor signaling, which may be essential for the maintenance of homeostasis of the immune system. Unlike CIS and SOCS-1–3, SOCS-4–7 have not been extensively studied (22Hilton D.J. Richardson R.T. Alexander W.S. Viney E.M. Willson T.A. Sprigg N.S. Starr R. Nicholson S.E. Metcalf D. Nicola N.A. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 114-119Crossref PubMed Scopus (606) Google Scholar). SOCS-6 and SOCS-7 have longer N-terminal domains than do CIS, SOCS-1, SOCS-2, and SOCS-3. Like other SOCS proteins, SOCS-6 binds to elongin B/C via the SOCS box domain (23Krebs D.L. Uren R.T. Metcalf D. Rakar S. Zhang J.G. Starr R. De Souza D.P. Hanzinikolas K. Eyles J. Connolly L.M. Simpson R.J. Nicola N.A. Nicholson S.E. Baca M. Hilton D.J. Alexander W.S. Mol. Cell. Biol. 2002; 22: 4567-4578Crossref PubMed Scopus (121) Google Scholar). In contrast to the other SOCS molecules studied, SOCS-6 does not interact with JAK and does not have any inhibitory effect on the signaling induced by the growth hormone, the leukemia inhibitory factor, or prolactin (24Ram P.A. Waxman D.J. J. Biol. Chem. 1999; 274: 35553-35561Abstract Full Text Full Text PDF PubMed Scopus (299) Google Scholar). However, a recent report indicates that SOCS-6 has direct effects on IR signaling in regard to reported interactions with the IR-(16) and SH2 domain-mediated interactions with the p85 subunit of phosphoinositide (PI) 3-kinase as well as IRS-2 and IRS-4 (23Krebs D.L. Uren R.T. Metcalf D. Rakar S. Zhang J.G. Starr R. De Souza D.P. Hanzinikolas K. Eyles J. Connolly L.M. Simpson R.J. Nicola N.A. Nicholson S.E. Baca M. Hilton D.J. Alexander W.S. Mol. Cell. Biol. 2002; 22: 4567-4578Crossref PubMed Scopus (121) Google Scholar). This finding would suggest that SOCS-6 might be involved in the regulation of glucose metabolism. However, mice with targeted disruption of the SOCS-6 gene do not display significant defects in glucose metabolism although they do display growth defects, weighing 8–10% less than wild type mice (23Krebs D.L. Uren R.T. Metcalf D. Rakar S. Zhang J.G. Starr R. De Souza D.P. Hanzinikolas K. Eyles J. Connolly L.M. Simpson R.J. Nicola N.A. Nicholson S.E. Baca M. Hilton D.J. Alexander W.S. Mol. Cell. Biol. 2002; 22: 4567-4578Crossref PubMed Scopus (121) Google Scholar). In the present study, we established transgenic mice overexpressing SOCS-6 to examine its function in vivo. SOCS-6 transgenics developed normally but displayed improved glucose and insulin tolerance. An insulin-induced interaction of SOCS-6 with the monomer form of the p85 subunit of PI 3-kinase was found and was associated with increased Akt/PKB activation induced by insulin. In addition, we found that SOCS-6 was induced by insulin but rapidly degraded by proteasome. Together, these findings indicate that SOCS-6 could play an important role in regulating insulin action in vivo. Antibodies—Mouse anti-human c-Myc monoclonal antibody (9E10) was purchased from BD Biosciences. Mouse monoclonal anti-phosphotyrosine (PY99) antibody, goat polyclonal anti-Akt/PKB antibody, and goat polyclonal anti-ERK antibody were purchased from Santa Cruz Biotechnology. Mouse monoclonal anti-phospho-ERK antibody, rabbit polyclonal anti-phospho-Akt/PKB antibody, and rabbit polyclonal anti-phospho-IR antibody were purchased from New England Biolabs. Rabbit polyclonal anti-p85 (αp85pan) antibody and anti-phospho-c-Jun N-terminal kinase were purchased from Upstate Biotechnology, Inc. The anti-phospho-IκB kinase was obtained from Cell Signaling Technology. The anti-SOCS-6 antiserum was generated by immunizing rabbits with a fusion protein encoding the SOCS-6 SH2 domain and the SOCS box (Fusion Antibodies, Belfast, Northern Ireland, UK). Generation of SOCS-6 Transgenic Mice—A murine full-length SOCS-6 cDNA was isolated from a mouse liver cDNA library (Stratagene). SOCS-6 cDNA tagged with the human c-Myc tag at its C terminus was cloned into the EcoRI and NotI sites of vector pEFneo under an elongation factor I promoter. Mice constitutively overexpressing the SOCS-6 transgene were established through an embryonic stem cell approach. Briefly, the vector-free pEF-SOCS-6-pSV40-neo fragment was transfected into E14 cells by electroporation. The Geneticin-resistant E14 clones were screened for SOCS-6 transgene expression by Western blotting with anti-c-Myc, and two of the positive clones were injected into blastocysts of C57BL/6. Both of the two clones successfully transmitted to the germ line, and the SOCS-6 transgenics was backcrossed five times to C57/BL6 background before phenotyping was performed. Metabolic Studies—To determine fasting blood glucose concentrations, two-month-old mice were starved overnight, and total blood was obtained by tail bleeding. All blood glucose concentrations were determined with a MediSense Optium glucometer and MediSense Optium electrodes (Abbott Laboratories). Glucose tolerance tests were performed after overnight fasting by intraperitoneal injection of 2g/kg d-glucose at time 0. Blood samples were taken at the indicated time points, and glucose levels were determined as described (Fig. 3b). For the insulin tolerance test, blood samples were obtained at indicated time points after intraperitoneal injection of 0.75 IU/kg human insulin (Sigma) (Fig. 3c). Plasma insulin levels in the serum from fasting animals were measured by an enzyme-linked immunosorbent assay using mouse insulin as a standard (Crystal Chem Inc., Chicago, IL). Hyperglycemic Clamps—Under anesthesia, a PE-10 tubing catheter was inserted into the left jugular vein and externalized through an incision in the skin flap behind the head. The mice were allowed to recover for 2 days. Before starting the experiments, mice fasted for 5 h. Then, through the implanted catheter, a 30% glucose solution was infused into the mice at the rates adjusted to maintain the blood glucose concentration at 10 mm, as determined from tail vein blood. Blood was collected after 2 h of performing the glucose clamp technique, and plasma insulin was determined by enzyme-linked immunosorbent assay. In Vivo Insulin Stimulation and Analysis of Insulin-signaling Proteins—Two-month-old mice were starved overnight, anesthetized with Hypnorm and Hypnovel, and 5 IU of human insulin (Sigma) was injected into the portal vein. Liver and muscles were removed at 3 and 5 min respectively, and instantly frozen in liquid nitrogen. Immunoprecipitation and immunoblot analysis of insulin-signaling molecules were performed on tissue homogenates extracted with homogenization buffer containing 1% Triton X-100, 50 mm HEPES (pH 7.4), 150 mm NaCl, 10 mm EDTA, 50 mm sodium pyrophosphate, 100 mm sodium fluoride, 10 mm sodium orthovanadate, 10 μg/ml aprotinin, 5 μg/ml leupeptin, 2 mm benzamidine, and 1 mm phenylmethylsulfonyl fluoride. Northern Blotting—For the study of the regulation of SOCS-6 expression by insulin stimulation, mouse embryo fibroblasts were isolated from embryonic day 13.5 embryos of C57BL/6 mice and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. After overnight or 4-h starvation of cells in Dulbecco's modified Eagle's medium without fetal bovine serum, the cells were stimulated with 1 μm human insulin at the indicated time points (Fig. 5), and total RNA was extracted with TRIzol (Invitrogen). To confirm SOCS-6 transgene expression in SOCS-6 transgenic mice, liver and muscles were isolated from 6–8 week-old wild type or SOCS-6 transgenics, and total RNA was extracted as described above. 30 μg of total RNA from each sample was fractionated on formaldehyde agarose gel and blotted onto Hybond N+ membrane (Amersham Biosciences). The SOCS-6 cDNA probe was a 1-kb fragment that spanned nucleotides 420 to 1434 in the SOCS-6 coding sequence. The glyceraldehyde-3-phosphate dehydrogenase cDNA probe was a 560-bp PCR fragment spanning nucleotides 40–600 in the glyceraldehyde-3-phosphate dehydrogenase coding sequence and served as the loading control. PI 3-Kinase Assay—Cleared cell lysates were immunoprecipitated using either a polyclonal anti-sera that recognized all forms of p85 (p85pan) or a monoclonal anti-phosphotyrosine antibody (PY99), washed three times with the tissue homogenization buffer and twice with PI 3-kinase reaction buffer (50 mm HEPES (pH 7.4), 100 mm NaCl, 0.5 mm EDTA, and 1 mm dithiothreitol), and then suspended in 35 μlof PI 3-kinase reaction buffer containing 0.2 mg/ml phosphatidylinositol (Sigma). The reactions were initiated by adding 15 μl of a MgCl2-ATP mixture (5 mm MgCl2 and100 μm ATP) containing 1 μCi of [γ-32P]ATP to the immunoprecipitates and incubated at room temperature for 20 min. The reaction was stopped by acidification. After the phosphorylated lipids were extracted and evaporated, the pellets were resuspended in 30 μl of chloroform/methanol (4:1), The phosphorylated lipids were separated by TLC and visualized by a phosphorimaging device. Proteasome Degradation Assay—For a pulse-chase assay with CHO cells, the cells were pulsed with [35S]methionine and [35S]cysteine master mix (Amersham Biosciences) after 4 h of starvation. The labeled cells were then incubated with insulin-containing medium, proteasome inhibitor LLnL (Sigma), or Me2SO. Cells were harvested and lysed at different time points (Fig. 6). The precipitates with different antibodies, as indicated (Fig. 6), were resolved by SDS-PAGE, dried, and visualized. Proteasome Degradation Assay with Cardiomyocyte—Primary neonatal cardiomyocytes were generated from SOCS-6 transgenics and cultured as described previously (25De Windt L.J. Lim H.W. Haq S. Force T. Molkentin J.D. J. Biol. Chem. 2000; 275: 13571-13579Abstract Full Text Full Text PDF PubMed Scopus (200) Google Scholar). Briefly, hearts were collected from 1–2-day-old SOCS-6 transgenics, the atrial tissue was removed, and the ventricles were cut into small pieces and digested with 0.05% pancreatin (Sigma) and 100 units/ml collagenase (Sigma) in phosphate-buffered saline. The cells were centrifuged at 1000 rpm for 5 min and cultured in M199 media (Invitrogen) with 15% fetal bovine serum. The non-myocytes were removed by incubation for 1 h in an uncoated dish. The enriched cardiomyocyte fractions were then plated on gelatin-coated plates and cultured for 16 h in serum-free M199 media. Cells were then treated with cycloheximide (1 μm) for 6 h to inhibit de novo syntheses of proteins in the cardiomyocytes. The treated cells were then incubated with insulin-containing medium, the proteasome inhibitor LLnL, or Me2SO. Cells were harvested and lysed at different time points (Fig. 6). The anti-p85 precipitates were resolved by SDS-PAGE and immunoblotted with anti-bodies against c-Myc for the detection of Myc-tagged SOCS-6, p85, and IRS-1, respectively. Generation of SOCS-6 Transgenic Mice—Two founder lines of transgenic mice were produced, each overexpressing the Myc-tagged SOCS-6 transgene at different levels (Fig. 1). Both lines were used for characterization of the phenotype. The expression levels of SOCS-6 in line 1 and line 2 were 5- and 10-fold higher, respectively, than those for wild type litter mates in liver, muscle, and T lymphocytes at either the mRNA (Fig. 1b) or protein level (Fig. 1a). All transgenic mice appeared to be healthy and grossly normal at baseline. They exhibited a normal reproductive rate, and the mortality rate over 12 months was the same as that for the wild type controls. Insulin Induces the Interaction of SOCS-6 and p85 Subunit of PI 3-Kinase—SOCS proteins were initially discovered to be the negative regulators of cytokine signaling, with SOCS-1, SOCS-2, SOCS-3, and CIS being associated with the down-regulation of JAK-STAT pathways (14Krebs D.L. Hilton D.J. J. Cell Sci. 2000; 113: 2813-2819Crossref PubMed Google Scholar). However, SOCS-6 and SOCS-7 have longer N-terminal domains than SOCS-1, -2, -3, and CIS (22Hilton D.J. Richardson R.T. Alexander W.S. Viney E.M. Willson T.A. Sprigg N.S. Starr R. Nicholson S.E. Metcalf D. Nicola N.A. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 114-119Crossref PubMed Scopus (606) Google Scholar), and, despite the structural homology in SH2 and SOCS domains to other SOCS proteins, SOCS-6 does not interact with JAK2 or inhibit signaling by growth hormone, leukemia inhibitory factor, or prolactin (24Ram P.A. Waxman D.J. J. Biol. Chem. 1999; 274: 35553-35561Abstract Full Text Full Text PDF PubMed Scopus (299) Google Scholar). This finding suggests that SOCS-6 may not be acting on cytokine-signaling pathways and, consistent with this possibility, we could not detect any suppressive function of SOCS-6 in lymphocytes stimulated by interleukin-2, interferon-γ, interleukin-4, granulocyte/macrophage colony-stimulating factor, and interleukin-12. 2L. Li, L. M. Grønning, P. O. Anderson, S. Li, K. Eduardsen, J. Johnston, D. Kioussis, P. R. Shepherd, and P. Wang, manuscript in preparation. The phosphorylation of STAT-1, -2, -4, -5, and -6 induced by cytokines was similar between the SOCS-6 transgenics and the wild type counterparts. 2L. Li, L. M. Grønning, P. O. Anderson, S. Li, K. Eduardsen, J. Johnston, D. Kioussis, P. R. Shepherd, and P. Wang, manuscript in preparation. While the mice were being generated it was reported that SOCS-6 could interact with IRS proteins and the p85 regulatory subunit of the class-Ia PI 3-kinase (23Krebs D.L. Uren R.T. Metcalf D. Rakar S. Zhang J.G. Starr R. De Souza D.P. Hanzinikolas K. Eyles J. Connolly L.M. Simpson R.J. Nicola N.A. Nicholson S.E. Baca M. Hilton D.J. Alexander W.S. Mol. Cell. Biol. 2002; 22: 4567-4578Crossref PubMed Scopus (121) Google Scholar). To investigate the possibility that these interactions could be occurring in our mice, we examined whether these proteins associated with the overexpressed SOCS-6. Transgenic mice were challenged with insulin, and anti-Myc antibodies were used to immunoprecipitate the SOCS-6 transgene product from liver extracts. The precipitates were Western blotted with antibodies specifically recognizing IRS-2, IRS-4, the IR, and p85, respectively. We could not detect neither the IR nor IRS-2 and IRS-4 in the co-precipitates (data not shown). However, the p85α subunit of PI 3-kinase was readily detected in the SOCS-6 co-precipitates (Fig. 2a). Moreover, the interaction of SOCS-6-Myc and p85 was only detected after stimulation with insulin (Fig. 2a). To confirm this interaction in another system, we transfected the SOCS-6-expressing construct into CHO-IR cells. Again, the interaction between p85α and SOCS-6 was readily detected, but only after insulin stimulation (Fig. 2b). However, no interaction between SOCS-6 and the IRS proteins was found (data not shown). Immunoprecipitation using an antibody that recognizes all isoforms of p85 showed that the wild type and transfected cells contained similar levels of p85 and the p110β catalytic subunit (Fig. 2b). In contrast, SOCS-6 immunoprecipitates from insulin-stimulated CHO-IR cells overexpressing SOCS-6 contained p85α but did not contain any p110β (Fig. 2b) which indicates the following: (i) that the p85α associated with SOCS-6 is a free monomer not bound to the catalytic subunit; and (ii) that the p85α associated with SOCS-6 is not recruited to the IRS proteins. The finding that insulin specifically recruits SOCS-6 to p85 monomers is very interesting, as there have been a number of recent studies indicating that p85 can have both positive and negative effects on insulin signaling and that the negative effects overcome the positive effects when high levels of a p85 monomer are present in cells (26Ueki K. Fruman D.A. Yballe C.M. Fassaur M. Klein J. Asano T. Cantley L.C. Kahn C.R. J. Biol. Chem. 2003; 278: 48453-48566Abstract Full Text Full Text PDF PubMed Scopus (174) Google Scholar, 27Ueki K. Fruman D.A. Brachmann S.M. Tseng Y.H. Cantley L.C. Kahn C.R. Mol. Cell. Biol. 2002; 22: 965-977Crossref PubMed Scopus (217) Google Scholar). Therefore, SOCS-6 could act as a physiologically relevant modulator of the effects of the p85 monomer, either mediating or attenuating the negative effects on insulin signaling. Improved Glucose Metabolism in SOCS-6 Transgenics—To test the effect of SOCS-6 on insulin action, we investigated glucose metabolism by insulin in SOCS-6 transgenic mice. We found lower fasting glucose levels in both lines of transgenic mice (84 ± 15 mg/dl for transgenic line 1 and 80 ± 18 mg/dl for transgenic line 2 versus 105 ± 33 mg/dl) as compared with the levels for wild type. (Fig. 3a). Both lines of mice also exhibited significant reductions in plasma glucose levels at all points in a glucose tolerance test as compared with the levels for wild type mice, and both lines also showed a significantly better clearance of glucose in an insulin tolerance test (Fig. 3, b and c). Furthermore, significantly higher levels of glucose transport stimulated by insulin were observed in mouse embryonic fibroblasts (MEFs) prepared from the SOCS-6 transgenics as compared with MEFs from control animals (Fig. 3d). The increased rate of glucose disposal could be due to increased insulin sensitivity in peripheral tissues, decreased hepatic glucose output, or increases in insulin secretion. The data from the insulin tolerance tests supports a role for increased insulin sensitivity, and this possibility is further supported by the finding that insulin levels were significantly lower in transgenic animals, both in the fasting state and 30 min after a glucose challenge (Fig. 3e). Furthermore, insulin levels remained lower in transgenic animals even when glucose levels had been clamped at 10 mm glucose for 120 min (Fig 3f). SOCS-6 Increases the Activity of Akt in Response to Insulin Stimulation—To examine the effect of SOCS-6 overexpression on insulin-mediated signaling, we investigated the activation of the IR, Akt/PKB, and the p42/p44 ERK. Overexpression of SOCS-6 in either the transgenic mice or CHO-IR cells did not affect the insulin-stimulated phosphorylation of the IR, the IRS, or the ERK (Fig. 4, a and b). In addition, the phosphorylation of IκB kinase and c-Jun N-terminal kinase in insulin-stimulated liver was also similar to that in wild type and SOCS-6 transgenic mice (data not shown). The recruitment of p85/p110 to insulin-signaling complexes was also una